BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 4, 2013
View Archived Issues
The Korea Institute of Ocean Science and Technology synthesizes novel agents for cancer
Read More
Vertex Pharmaceuticals discloses new agents for influenza
Read More
New agents that inhibit AIMP2-DX2 selected by Korean researchers
Read More
XOMA-3AB well tolerated in phase I study
Read More
Tulane University researchers describe B. pseudomallei vaccine strategy
Read More
Takeda Pharmaceutical synthesizes new inhibitors of ROR gamma t
Read More
Dainippon Sumitomo Pharma divulges new neutrophil elastase inhibitors
Read More
Pooled phase Ib results for dupilumab show efficacy in atopic dermatitis
Read More
Second phase III trial of tavaborole in onychomycosis meets endpoints
Read More
Cubist Pharmaceuticals obtains QIDP and fast track designations for late-stage antibiotic candidates
Read More
FluoroPharma Medical reports data from phase II CardioPET study
Read More
Kythera Biopharmaceuticals presents phase III results for ATX-101
Read More
Adventrx Pharmaceuticals to change name, provides update on ANX-188
Read More
BioAlliance Pharma signs agreement with global vaccine company
Read More
Progen signs licensing agreement for PG-545
Read More
Pseudomonas-specific antibiotic POL-7080 completes phase I study
Read More
Novo Nordisk launches new long-acting insulin Tresiba in Denmark
Read More
Santhera considering strategic options following decisions regarding Catena and Raxone
Read More
NeuroDerm completes phase I study of levodopa/carbidopa patch pump
Read More
Enrollment completed in phase II study of PsiOxus' MT-102 for cancer cachexia
Read More
FDA approves revised SPA for phase III trial of Collategene in critical limb ischemia
Read More
FDA approves expanded indication for Corifact
Read More
miRNAs as novel targets in androgen-independent prostate cancer
Read More
UCLA receives funding to identify genetic changes that affect the severity of DMD
Read More
Companies partner to advance allosteric modulators targeting adenosine A2A receptor
Read More
Alere receives Gates Foundation grant to develop tuberculosis assay
Read More